RedHill Biopharma Ltd. (RDHL) Key Metrics

NASDAQ: RDHLValuation, returns, debt and efficiency ratios over 10 years.

RDHL valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$4.3M
Enterprise value
$413,101
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
10.2
Price / book
0.8
EV / EBITDA
0.3
Dividend yield
—
Beta
4.90

RDHL key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

RDHL valuation Price multiples at each fiscal year-end price.

Price / sales+497.9%
11.4
2025 · hover or tap a bar for each year
2024: 1.92025: 11.4 (+497.9%)
20162025
Free cash flow yield−235.5 pts
−296.7%
2025 · hover or tap a bar for each year
2024: −61.3%2025: −296.7% (−235.5 pts)
20162025

RDHL valuation history

Fiscal year-endToday10-year median

RDHL returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

RDHL debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

RDHL price vs earnings per share

Share price at year-endEPS (right axis)

RDHL key metrics

2016–2025
RedHill Biopharma Ltd. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$3.3M$15.3M————————
Enterprise value$352,950$11.0M————————
Price / sales11.41.9————————
Price / book0.8—————————
EV / sales1.21.4————————
Earnings yield−13.2%−54.0%————————
Free cash flow yield−296.7%−61.3%————————
Share price at fiscal year-end$1.03$6.21$36.50$140.30$2,580.00$8,080.00$6,070.00$5,550.00$5,140.00$10,460.00
Per share
Revenue per share$0.09$3.26————————
Earnings per share−$0.14−$3.35————————
Operating cash flow per share−$3.05−$3.80————————
Free cash flow per share−$3.06−$3.81————————
Cash per share$1.26$1.87————————
Book value per share$1.35−$1.90————————
Tangible book value per share−$0.32−$4.15————————
Capex per share$0.00$0.00————————
Debt per share$0.34$0.14————————
Shares outstanding3.2M2.5M————————
Change in shares outstanding+28.2%—————————
Returns & profitability
Return on equity (ROE)————−859.7%−206.2%−76.1%−80.7%−84.5%−47.8%
Return on invested capital (ROIC)———−59.9%−98.9%−115.8%−489.4%——−821.0%
Return on assets (ROA)−2.0%−40.2%26.3%−42.2%−54.1%−59.9%−62.0%−64.8%−69.2%−41.6%
Return on tangible assets−2.1%−66.2%136.9%−76.9%−89.2%−82.5%−74.0%−68.0%−87.5%−43.1%
Free cash flow margin—−116.6%−548.7%−47.5%−76.0%−159.0%−651.0%−412.9%——
Income quality (OCF / net income)——−1.50———————
Financial health
Total debt$1.1M$356,000$1.2M$122.7M$87.8M$86.9M$3.8M—$448,000$6.2M
Cash & short-term investments$4.0M$4.6M$6.4M$20.0M$38.0M$29.8M$47.9M$53.2M$46.2M$66.2M
Net debt−$2.9M−$4.3M−$5.2M$102.7M$49.8M$57.1M−$44.1M−$53.2M−$45.8M−$60.0M
Debt / equity0.25—0.57—9.896.270.06—0.010.10
Debt / assets0.040.020.050.770.480.480.05—0.010.08
Net debt / EBITDA——−0.20———————
Current ratio0.340.540.840.441.090.965.015.474.3712.66
Quick ratio0.340.370.610.380.910.874.845.404.3112.45
Interest coverage-416.3-265.734.4-1.0-4.9-5.1-98.3-235.5-675.0—
Working capital−$12.7M−$10.3M−$3.1M−$111.6M$7.7M−$2.7M$42.6M$46.4M$39.8M$62.5M
Invested capital$1.4M−$8.9M−$3.1M$54.3M$58.7M$71.0M$15.9M−$2.0M−$692,000$2.7M
Tangible asset value−$1.0M−$10.2M−$3.5M−$114.0M−$62.8M−$74.0M$43.1M$45.9M$39.8M$56.6M
Net current asset value−$14.5M−$10.8M−$4.8M−$121.4M−$83.2M−$95.9M$39.1M$45.6M$39.4M$56.3M
Graham net-net per share−$4.83−$5.52————————
Capital allocation
Share buybacks (net)——————$0$0$0$0
Capex / revenue1.7%0.1%0.2%0.3%0.1%83.6%3.2%0.7%29.5%118.8%
Capex / depreciation0.010.010.010.020.016.150.170.6414.582.73
Stock-based compensation / revenue159.8%8.3%25.2%9.2%11.9%6.5%48.1%32.0%55.8%1,662.4%
R&D / revenue707.3%19.7%54.0%11.8%34.4%25.6%276.9%297.4%822.8%24,991.1%
SG&A / revenue2,158.0%192.9%442.3%103.6%102.6%116.0%473.9%239.1%500.1%5,349.5%
Efficiency
Days sales outstanding3,857.4155.51,150.3207.9131.587.787.979.8125.41,286.5
Days of inventory on hand—459.7812.4141.378.841.6214.291.5151.7-199.3
Days payables outstanding—636.9396.187.085.877.8606.6522.9417.61.1
Cash conversion cycle (days)—-21.71,566.6262.2124.651.4-304.5-351.6-140.51,086.2
Receivables turnover0.092.350.321.762.774.164.154.572.910.28
Payables turnover0.000.570.924.194.264.690.600.700.87341.26
Inventory turnover—0.790.452.584.638.781.703.992.41—
Asset turnover0.010.390.070.360.470.510.090.140.060.00
Average receivables$3.0M$3.4M$20.6M$35.2M$30.9M$15.5M$1.5M$1.8M$1.4M$356,000
Average payables$7.1M$5.6M$3.8M$7.9M$11.6M$7.9M$3.8M$4.1M$2.4M$89,500
Average inventory$1.8M$4.0M$7.7M$12.9M$10.7M$4.2M$1.3M$711,000$883,500−$16.7M
Intangibles / total assets20.9%30.7%24.2%41.3%39.5%48.8%22.8%8.5%9.2%8.2%

Computed from RDHL's annual financial statements (latest annual report filed April 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

RDHL valuation and financial ratios

It ended the year with $1.1 million of debt and $4.0 million in cash and short-term investments, a net cash position of $2.9 million.

See the RDHL income statement, the RDHL chart for price history, or the RDHL stock overview for the latest quote and news.

RDHL key metrics FAQ

How much debt does RedHill Biopharma have?

RedHill Biopharma had total debt of $1.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.25 and more cash than debt.

What is RedHill Biopharma's free cash flow yield?

RedHill Biopharma generated -$9.7 million of free cash flow in fiscal 2025, a free cash flow yield of −296.7% on its market value at year-end ($3.3 million).

What is RedHill Biopharma's current ratio?

RedHill Biopharma's current ratio was 0.34 at the end of fiscal 2025: current assets were 0.34 times current liabilities.

Drug Manufacturers - Specialty & Generic key metrics